Detalhe da pesquisa
1.
Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 18(1): 123-132.e3, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31077827
2.
Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.
Clin Gastroenterol Hepatol
; 17(8): 1541-1550, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30476584
3.
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
Gut
; 66(6): 1049-1059, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28209624
4.
Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study.
Aliment Pharmacol Ther
; 49(3): 265-276, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30663107
5.
Active hospital-based surveillance of invasive pneumococcal disease and clinical pneumonia in infants and young children in two Polish counties.
Arch Med Sci
; 12(3): 629-38, 2016 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27279858
6.
Long-term immune responses to pneumococcal conjugate vaccines in children previously vaccinated with 7-valent pneumococcal conjugate vaccine.
Pediatr Infect Dis J
; 32(9): 990-7, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24008739
7.
Prospective surveillance study of invasive pneumococcal disease among urban children in the Philippines.
Pediatr Infect Dis J
; 32(10): e383-9, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23629024